复发慢性淋巴细胞白血病中抗CD19嵌合抗原受体T细胞的随机剂量优化研究长期结局
2013年1月至2016年6月纳入42例复发或难治性慢性淋巴细胞白血病患者,38例输注抗CD19嵌合抗原受体T细胞(CART-19),其中28例随机接受低剂量(5×10^7)或高剂量(5×10^8),24例可评估疗效;中期分析后10例接受选定高剂量,8例可评估。中位随访31.5个月(范围2至75个月)。4周时32例可评估患者完全缓解率28%(90%CI 16%至44%),总缓解率44%(90%CI 29%至60%)。
要点
- 4周时32例可评估患者完全缓解率28%,总缓解率44%。
- 所有患者中位总生存期64个月,低剂量与高剂量组间无统计学显著差异(P=.84)。
- 达到完全缓解者中位总生存期未达到,未达到者64个月(P=.035)。
核心结论
- 在晚期慢性淋巴细胞白血病患者中,5×10^8剂量CART-19在诱导完全缓解方面可能比5×10^7更有效,且不增加过度毒性。
- 无论细胞剂量如何,输注CART-19后达到完全缓解与更长的总生存期和无进展生存期相关。
研究设计与样本
- 2013年1月至2016年6月纳入42例复发或难治性慢性淋巴细胞白血病患者,38例输注抗CD19嵌合抗原受体T细胞(CART-19)。
- 28例初始随机接受低剂量(5×10^7)或高剂量(5×10^8)CART-19,24例可评估疗效;中期分析后10例接受选定高剂量,8例可评估疗效。
- 中位随访31.5个月(范围2至75个月)。
主要发现
- 4周时32例可评估患者完全缓解率为28%(90%CI 16%至44%),总缓解率为44%(90%CI 29%至60%)。
- 所有患者中位总生存期为64个月;低剂量组与高剂量组间无统计学显著差异(P=.84)。
- 达到完全缓解者中位总生存期未达到,未达到完全缓解者为64个月(P=.035)。
- 达到完全缓解者中位无进展生存期为40.2个月,未达到完全缓解者为1个月(P<.0001)。
- 两个剂量组毒性相当。
临床怎么用
- 作者认为,在晚期慢性淋巴细胞白血病患者中,5×10^8剂量CART-19在诱导完全缓解方面可能比5×10^7更有效,且不增加过度毒性。
- 作者认为,输注CART-19后达到完全缓解与更长的总生存期和无进展生存期相关,与细胞剂量无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe long-term outcomes of anti-CD19 chimeric antigen receptor T (CART) cells in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). METHODS: Between January 2013 and June 2016, 42 patients with relapsed or refractory CLL were enrolled in this study and 38 were infused with anti-CD19 CART cells (CART-19). Of these, 28 patients were initially randomly assigned to receive a low (5 × 107) or high (5 × 108) dose of CART-19, and 24 were evaluable for response assessment. After an interim analysis, 10 additional patients received the selected (high) dose and of these, eight were evaluable for response. Patients were followed for a median 31.5 months (range, 2 to 75 months). RESULTS: At 4 weeks, the complete and overall responses for the 32 evaluable patients were 28% (90% CI, 16% to 44%) and 44% (90% CI, 29% to 60%), respectively. The median overall survival (OS) for all patients was 64 months; there was no statistically significant difference between low- and high-dose groups (P = .84). Regardless of dose, prolonged survival was observed in patients who achieved a CR versus those who did not (P = .035), with median OS not reached in patients with CR versus 64 months in those without CR. The median progression-free survival was 40.2 months in patients with CR and 1 month in those without a CR (P < .0001). Toxicity was comparable in both dose groups. CONCLUSION: In patients with advanced CLL, a 5 × 108 dose of CART-19 may be more effective than 5 × 107 CART-19 at inducing CR without excessive toxicity. Attainment of a CR after CART-19 infusion, regardless of cell dose, is associated with longer OS and progression-free survival in patients with relapsed CLL.
引用
- Frey NV, Gill S, Hexner EO, et al. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2020. PMID: 32298202. doi:10.1200/JCO.19.03237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。